These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24061458)

  • 1. P-glycoprotein expression as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Vishnukumar S; Umamaheswaran G; Anichavezhi D; Indumathy S; Adithan C; Srinivasan K; Kadambari D
    Indian J Cancer; 2013; 50(3):195-9. PubMed ID: 24061458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
    Chintamani ; Singh JP; Mittal MK; Saxena S; Bansal A; Bhatia A; Kulshreshtha P
    World J Surg Oncol; 2005 Sep; 3():61. PubMed ID: 16164742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
    Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O
    Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.
    Zhang K; Yuan K; Wu H; Li Q; Wang Y; Chen S; Zhang L; Gu H; Fu R
    Appl Biochem Biotechnol; 2012 Feb; 166(3):753-63. PubMed ID: 22127810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
    Chen YZ; Xue JY; Chen CM; Yang BL; Xu QH; Wu F; Liu F; Ye X; Meng X; Liu GY; Shen ZZ; Shao ZM; Wu J
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):637-44. PubMed ID: 22903535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
    Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
    Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Huober J; von Minckwitz G; Denkert C; Tesch H; Weiss E; Zahm DM; Belau A; Khandan F; Hauschild M; Thomssen C; Högel B; Darb-Esfahani S; Mehta K; Loibl S
    Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
    Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
    NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
    J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neoadjuvant chemotherapy on the quantitative expression of P-gp, LRP, MRP, GST-π in NSCLC and its clinical significance.
    Xiang F; Yu W; Shen Y; Wu C; Wang Y
    Zhongguo Fei Ai Za Zhi; 2007 Oct; 10(5):398-405. PubMed ID: 21126409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
    Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
    J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.